Akoya Biosciences (AKYA) Stock Forecast & Price Target

$2.89

-0.14 (-4.62%)

(As of 10/10/2024 ET)

Akoya Biosciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 9 Analyst Ratings

Sell
0

Hold
4

Buy
5

Based on 9 Wall Street analysts who have issued ratings for Akoya Biosciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 4 have given a hold rating, and 5 have given a buy rating for AKYA.

Consensus Price Target

$6.56
127.08% Upside

According to the 9 analysts' twelve-month price targets for Akoya Biosciences, the average price target is $6.56. The highest price target for AKYA is $10.00, while the lowest price target for AKYA is $3.00. The average price target represents a forecasted upside of 127.08% from the current price of $2.89.

Get the Latest News and Ratings for AKYA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Akoya Biosciences and its competitors.

AKYA Analyst Ratings Over Time

Type	Current Forecast 10/11/23 to 10/10/24	1 Month Ago 9/11/23 to 9/10/24	3 Months Ago 7/13/23 to 7/12/24	1 Year Ago 10/11/22 to 10/11/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	8 Buy rating(s)	4 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$6.56	$6.56	$7.25	$14.33
Forecasted Upside	127.08% Upside	148.58% Upside	213.85% Upside	288.44% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

Bigger Than Nvidia? (Ad)

Bigger Than Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that's all they'll talk about.

Go here now for this breaking story.

AKYA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AKYA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Akoya Biosciences Stock vs. The Competition

Type	Akoya Biosciences	Medical Companies	S&P 500
Consensus Rating Score	2.56	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	127.08% Upside	9,907.36% Upside	7.77% Upside
News Sentiment Rating	Neutral News See Recent AKYA News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/13/2024	Piper Sandler 2 of 5 stars		Lower Target	Overweight ➝ Overweight	$6.00 ➝ $4.00	+73.91%
8/6/2024	Morgan Stanley 3 of 5 stars		Downgrade	Overweight ➝ Equal Weight	$4.00 ➝ $3.00	+50.00%
8/6/2024	Craig Hallum 3 of 5 stars	B. Bonello Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$7.50 ➝ $7.00	+241.46%
8/6/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Massaro Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/6/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral
5/14/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$10.00 ➝ $6.00	+109.79%
Get the Latest News and Ratings for AKYA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Akoya Biosciences and its competitors with MarketBeat's FREE daily newsletter.
3/5/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$7.00 ➝ $7.50	+40.71%
12/14/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral
11/13/2023	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$14.00 ➝ $9.00	+126.70%
11/3/2022	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Chiang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$19.00	+42.64%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 12:31 AM ET.

AKYA Forecast - Frequently Asked Questions

: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Akoya Biosciences is $6.56, with a high forecast of $10.00 and a low forecast of $3.00.
: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akoya Biosciences in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AKYA shares.
: According to analysts, Akoya Biosciences's stock has a predicted upside of 127.08% based on their 12-month stock forecasts.
: Over the previous 90 days, Akoya Biosciences's stock had 3 downgrades by analysts.
: Akoya Biosciences has been rated by research analysts at BTIG Research, Craig Hallum, JPMorgan Chase & Co., Morgan Stanley, and Piper Sandler in the past 90 days.
: Analysts like Akoya Biosciences less than other "medical" companies. The consensus rating score for Akoya Biosciences is 2.56 while the average consensus rating score for "medical" companies is 2.79. Learn more on how AKYA compares to other companies.